Nocloprost, a novel prostanglandin E2 analog: significant reduction of aspirin induced grastrointestinal lesions in man.
Dammann
H G
HG
Krankenhaus Bethanien, Hamburg, F.R.G.
Dreyer
M
M
Walter
T A
TA
Müller
P
P
Simon
B
B
Wabnitz
R W
RW
D000328:Adult; D001241:Aspirin / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004386:Duodenum / Q000187:drug effects / Q000473:pathology; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects / Q000473:pathology*; D008297:Male; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*
D011461:Prostaglandins F, Synthetic; C048895:nocloprost; D001241:Aspirin